New drug combo aims to tackle tough lung cancer
NCT ID NCT07079475
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination of two oral drugs, DZD6008 and sunvozertinib, in 160 adults with advanced non-small cell lung cancer that has certain EGFR mutations. The goal is to check safety, how the drugs move through the body, and whether they shrink tumors. It is the first time this combination is being tested in humans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DZD6008 combined with sunvozertinib
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced lung cancer that has specific genetic changes.
- What could go wrong
- This is an early-phase trial (Phase I/II) with only 160 participants, so the combination may not prove effective or safe enough for wider use. Side effects are unknown and being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Chest Hospital
RECRUITINGBeijing, Beijing Municipality, 101125, China
-
First Affilicated Hospital of China Medical University
NOT_YET_RECRUITINGShengyang, Liaoning, China
-
Hangzhou Cancer Hospital
NOT_YET_RECRUITINGHangzhou, Zhejiang, China
-
Harbin Cancer Hospital
NOT_YET_RECRUITINGHarbin, Heilongjiang, China
-
Hunan Cancer Hospital
NOT_YET_RECRUITINGChangsha, Hunan, China
-
Jiangsu People's Hospital
NOT_YET_RECRUITINGNanjing, Jiangsu, China
-
Nanjing Gulou Hospital
RECRUITINGNanjing, Jiangsu, China
-
Shandong Cancer Hospital
RECRUITINGJinan, Shandong, 250117, China
-
Shanghai Chest Hospital
RECRUITINGShanghai, Shanghai Municipality, 200030, China
-
Sichuan Cancer Hospital
RECRUITINGChengdu, Sichuan, 6100042, China
-
The First Affiliated Hospital of Guangzhou Medical University
RECRUITINGGuangzhou, Guangdong, China
-
The First Affilicated Hospital of Xi'An Jiaotong University
NOT_YET_RECRUITINGXi’an, Shanxi, China
-
The First Hospital of Jilin University
NOT_YET_RECRUITINGChangchun, Jilin, China
-
Tianjin Cancer Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
-
West China Hospital, Sichuan University
NOT_YET_RECRUITINGChengdu, Sichuan, China
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310005, China
-
Zhejiang Taizhou Hospital
RECRUITINGTaizhou, Zhejiang, 317000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?